1. Zelceski, Anabel, Francica, Paola, Lingg, Lea, Rottenberg, Sven, Lord, Christopher J. 2023. MND1 and PSMC3IP control PARP inhibitor sensitivity in mitotic cells. In Cell reports, 42, 112484. doi:10.1016/j.celrep.2023.112484. https://pubmed.ncbi.nlm.nih.gov/37163373/
2. Capdevila-Busquets, Eva, Badiola, Nahuai, Arroyo, Rodrigo, Soler-López, Montserrat, Aloy, Patrick. 2015. Breast cancer genes PSMC3IP and EPSTI1 play a role in apoptosis regulation. In PloS one, 10, e0115352. doi:10.1371/journal.pone.0115352. https://pubmed.ncbi.nlm.nih.gov/25590583/
3. Ding, Jingli, Li, Yang, Fan, Huxiong, Yang, Juesheng, Zhou, Jianliang. 2018. Knockdown of PSMC3IP suppresses the proliferation and xenografted tumorigenesis of hepatocellular carcinoma cell. In Journal of cellular biochemistry, 120, 5449-5458. doi:10.1002/jcb.27824. https://pubmed.ncbi.nlm.nih.gov/30362169/
4. Zangen, David, Kaufman, Yotam, Zeligson, Sharon, Renbaum, Paul, Levy-Lahad, Ephrat. 2011. XX ovarian dysgenesis is caused by a PSMC3IP/HOP2 mutation that abolishes coactivation of estrogen-driven transcription. In American journal of human genetics, 89, 572-9. doi:10.1016/j.ajhg.2011.09.006. https://pubmed.ncbi.nlm.nih.gov/21963259/